Excellent safety, efficacy, and tolerability profiles have resulted in the rapid integration of oral tyrosine kinase inhibitors into most facets of the treatment of gastrointestinal stromal tumors (GIST).
James C. Watson, MD
Advertisement
Articles by James C. Watson, MD
Advertisement
Latest Updated Articles
- Perioperative Tyrosine Kinase Inhibitors for GIST: Standard . . . or an Idea That Needs Further Investigation?
Published: January 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC
2
FDA Grants Regular Approval to Rucaparib in Metastatic CRPC
3
Imlunestrant Combo Will Not Be Pursued for FDA Approval in Breast Cancer
4
Gathering Data to Ascertain Biomarker Specificity in HER2– Breast Cancer
5